Roche announced today that it is integrating more than 20 new artificial intelligence (AI) algorithms from eight new collaborators into its Roche Digital Pathology Open Environment for cancer diagnostics.
The Roche Digital Pathology Open Environment is a strategic collaboration aimed at bringing together a range of AI-based pathology tools from contributors to support pathologists and scientists in cancer research and diagnosis.
The integration of the AI-based tools is facilitated through Roche's Navify Digital Pathology enterprise software. In a statement, Roche noted that Navify now incorporates a diverse range of AI-driven algorithms, which allows for easy access to third-party tools for enhanced pathology insights, in turn benefiting cancer patients through precision medicine and enabling targeted treatments.
The new collaborators and algorithms include the following:
- Deep Bio: An algorithm for prostate cancer detection, grading, and tumor quantification
- DiaDeep: Algorithms for breast cancer biomarker quantification
- Lunit: A tumor proportion score analysis for non-small cell lung cancer
- Mindpeak: Algorithms for breast biomarkers and pan-tumor PD-L1 for lung, gastric, esophageal, bladder, and breast cancers
- Owkin: An algorithm for screening for microsatellite stability in colorectal cancer
- Qritive: Algorithms for screening for and grading prostate cancer, analyzing lymph nodes for metastasis, and screening for colon cancer
- Sonrai Analytics: An algorithm for determining microsatellite instability status in colorectal cancer
- Stratipath: An algorithm for risk profiling of invasive breast cancer
